Vivid Seats says it expects to return to top-line growth in the second half of the year
Vivid Seats (NASDAQ:SEAT) traded lower in early action on Wednesday after the company posted a net loss for the quarter.
Healio28d
VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than 80% of Omvoh responders from the VIVID-1 ...
clinicaladvisor.com11d
Mirikizumab in Crohn Disease: Insights From the VIVID-1 and VIVID-2 Trials
The VIVID-1 and VIVID-2 clinical trials were conducted to evaluate its efficacy and safety in patients with moderately to severely active CD. VIVID-1, a phase 3 randomized controlled trial ...
Pharmabiz1mon
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...
Fintel on MSN1d
B of A Securities Downgrades Vivid Seats (SEAT)
Fintel reports that on March 13, 2025, B of A Securities downgraded their outlook for Vivid Seats (NasdaqGS:SEAT) from Buy to ...
Vivid Seats Releases Inaugural 2025 MLB Fan Loyalty Report
Data Reveals Baseball Fan Allegiances and MLB Season Trends Vivid Seats 2025 MLB Fan Loyalty Infographic 1 Vivid Seats data ...